Skip to main content
Eligibility
for people ages 18 years to 99 years
Location
at San Francisco, California and other locations
Dates
study started
estimated completion:
Principal Investigator

Description

Summary

To allow continuation of treatment of patients experiencing benefit from AG 013736

Official Title

Continuing Access To The Tyrosine Kinase Inhibitor Of Vegfr 2, Ag 013736 (a406) For Patients Previously Receiving Ag 013736 In Clinical Trials

Keywords

Solid Tumors VEGFR inhibitor angi-angiogenic tyrosine kinase inhibitor Axitinib

Eligibility

You can join if…

Open to people ages 18 years to 99 years

  • Patients who were assigned to an axitinib containing treatment arm in a previous clinical trial
  • Patients who were receiving axitinib tablets at the time their previous trial ended
  • Patients who have stable (SD) or responding disease (PR or CR) documented by the appropriate radiological, clinical, or laboratory assessments within 12 weeks before enrollment (Note: response criteria from the previous AG-013736 protocol should be used to determine stable or responding disease).
  • Patients who have progressive disease (PD) but have experienced "clinical benefit" as defined in the study protocol

You CAN'T join if...

  • Patients may not participate in this trial if the conditions for continuing treatment in the previous AG-013736 protocol are not met

Locations

  • UC Irvine Medical Center
    Orange, California, 92868, USA
  • University of California Irvine Medical Center - Chao Family Comprehensive Cancer Center
    Orange, California, 92868, USA
  • UCLA Hematology-Oncology-Santa Monica
    Santa Monica, California, 90404, USA

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Pfizer
Links
To obtain contact information for a study center near you, click here.
ID
NCT00828919
Lead Scientist
Charles Ryan
Study Type
Interventional
Last Updated
February 2017